Arctic Bioscience is a Norwegian biotechnology company focused on developing, manufacturing and marketing premium ingredients extracted from herring roe.

The Company raised NOK 300 million through an offering of new shares. In addition, there was an over-allotment (greenshoe option) bringing total proceeds raised in the offering to NOK 345 million. The private placement attracted strong interest from Norwegian and international investors, and was multiple times oversubscribed. The shares in the new issue were sold at NOK 31.00 corresponding to a market capitalisation of NOK 753 million.

Saga Corporate Finance acted as strategic advisor to the Company and board of directors.